Clinical-stage biotech developing a reversal agent for intracranial haemorrhage.
| Date | Round | Amount |
|---|---|---|
| Dec 2024 | Seed Dutch biotech Alveron Pharma raised a EUR 5M Series Seed extension led by Broadview Ventures to advance its drug OKL-1111 for intracranial haemorrhage. | $5.3M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.